Quote | Lyra Therapeutics Inc. (NASDAQ:LYRA)
Last: | $4.72 |
---|---|
Change Percent: | 0.19% |
Open: | $5.16 |
Close: | $4.72 |
High: | $5.2 |
Low: | $4.7001 |
Volume: | 157,109 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Lyra Therapeutics Inc. (NASDAQ:LYRA)
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
2023-04-25 08:55:36 ET Lyra Therapeutics ( NASDAQ: LYRA ) said it had resumed screening and enrollment for its second Phase 3 clinical trial of LYR-210 to treat chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant and acts as an alternative to sinus surgery...
Message Board Posts | Lyra Therapeutics Inc. (NASDAQ:LYRA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: LYRA 22% v5,2M c5.28 f13M H6.10 ML3.81 | znewcar1 | investorshangout | 04/09/2022 2:01:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing inn...
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnol...
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...